David

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

• They earn high returns on the capital they employ.
• They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
• They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers prove that Intuitive Surgical (ISRG) is one of the top EVA Monsters that we have analyzed so far, so it is worthy of your close attention. This company has a deep moat, coupled with the tailwind of strong expected growth in the robotic surgery market.

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

• They earn high returns on the capital they employ.
• They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
• They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers prove that IDEXX (IDXX), being at the forefront of the animal health industry is a genuine EVA Monster, so it is worthy of your close attention. The pool of public companies that directly benefit from the humanization of pets’ megatrend is very shallow, and this firm stands out as one of the best opportunities to ride this multi-decade secular tailwind.

Let’s recap what we’ve learned so far. We’ve realized that instead of constantly changing your target list, it makes sense to maintain a relatively stable investment universe whose members meet your fundamental criteria. You should aim to curate a shortlist of “investable universe” containing outstanding companies that you closely follow. You can then allow Mr. Market to do its job with its bipolar ups and downs, hoping that sentiment shifts in your favor by offering a few of the candidates in your investable universe for sale.

We’ve also seen that quantitative screening is just the beginning and not the end, even though it can provide valuable inputs for an investment process. The list of companies that match your screening criteria is only the starting point; this is where the comprehensive qualitative analysis begins.

This way, you can form an educated opinion and make a contrarian bet at the point when you have an unwavering understanding of the underlying business, differentiating between temporary challenges and existential threats. This concept aligns with the saying that success occurs when opportunity meets preparation.

Now, onto the most challenging part.

Let’s suppose you agree with the laid-out process so far and would like to set sail to navigate it on your own. Great!

First, you want to rely on the best fundamental data to build your financial models, right?

You have the option to calculate this data manually for your targets, which would entail an Excel sheet with over a thousand lines for each company. Not so charming, is it?

And even then, you won’t have the ability to conduct a screening, as you lack a tool that can filter through years of historical data for thousands of public companies. Therefore, the only viable option is a data provider, which comes with a significant cost, often in the tens of thousands of dollars, as this is the price tag for institutional-level metrics.

Let’s assume we have taken care of this step for you…

Now you’re prepared to dive into what your screener identifies and put in the rigorous effort to separate the outstanding from the mediocre, compiling a list of truly high-quality compounders that will form the foundation of your investment universe. Just to give you an idea: our team of three analysts spent three full years completing the qualitative assessment of 60 EVA Monster candidates. If you’re doing it on your own, this adds up to a demanding decade of full-time work. Furthermore, you might have to start anew as some of the information you’ve gathered will inevitably become outdated over time.

As astonishing as this may sound, we hope that your passion for individual stocks still burns brightly, and that you’re not fond of the idea of entrusting your money to a fund manager for high fees (and the likelihood of underperformance). You probably don’t want to passively invest all your money with no control, do you?

The good news is there’s a shortcut. As a subscriber to the FALCON Method Newsletter, you gain instant access to:

• The full list of approximately 60 quality-growth-focused EVA Monster candidates, updated yearly to incorporate new promising entries and eliminations as our conviction wanes.
• On top of that, a monthly execution of our value-focused screening process, searching for “Fallen Angel” value opportunities from a preselected universe, based on a solid dividend history.
• A monthly newsletter featuring a complete factsheet of the 10 most promising targets, including the top “EVA Monster” and “Fallen Angel” prospects, exclusively ranked by our modeled 5-year total return potential.
• A list of our top picks each month, where we have the highest conviction and invest our capital.
• An educational-focused opening piece designed to enhance your skills as an investor by offering timeless lessons on the market, insights into investment psychology, as well as our efforts to broaden your circle of competence by shedding light on secular trends, or business case studies.

Here is an excerpt from the opening piece of the November 2023 issue, which explains how our contrarian bet on Meta played out by emphasizing the crucial aspects of its fundamental puzzle:

”Meta served as the perfect example of how a company can respond to challenges in a moat-enhancing way. Handling the Apple privacy issue with in-house machine learning solutions, fending off the emerging threat from TikTok, and actively preparing for the next wave of computing platform change all made the business more resilient. While the stock was punished, sub-$100 Meta was doing all the right things to defend and even strengthen its moat, which was well rewarded by now. Again, competitive dynamics drive stock prices; it’s just not easy to measure and monitor them.”

As a final takeaway, here is a quick recap of the 7 steps of the FALCON Method:

Step#1: Screen for Top-Quality
When a business consistently earns high returns on its invested capital and operates with spectacular margins (measured by the percentage of sales resulting in real economic profit), these are telltale signs of an existing moat.

Step#2: Growth is needed to drive performance
To qualify as a truly outstanding business, a top-quality company must also have growth opportunities that allow it to reinvest most of its cash flows at high rates of return.

Step#3: Introducing the EVA Monsters
Quality alone is not sufficient, while growth without quality is exceedingly risky. However, the combination of quality and growth offers phenomenal performance.

Step#4: The windshield approach to rank the Monsters
While we selected the members of this elite group with the help of historical data, we use forward-looking modeling to determine which of them are the most promising investment candidates and are thus worthy of our attention.

Step#5: Read, read, read… The qualitative aspects
Once we have those polished Excel models, we delve deep to gain a better understanding of the business. Our primary focus points in the analysis include the sources and sustainability of the moat, capital allocation, the drivers of growth, and management’s integrity.

Step#6: Fine-tuning and Conviction
We determine two entry price levels. The first (and higher) one is the buy price with the potential to provide a 15% annualized total return over a 5-year timeframe, assuming our assessment of the firm’s fundamental performance is accurate and the valuation remains within its typical historical range. We also establish a lower, very conservative entry price, which we refer to as our “5-star” or “punchcard” price.

Step#7: Who could beat the highest-ranking Monsters?
By this stage, we know exactly which EVA Monsters (quality-growth stocks) present the most attractive opportunities in the market. Rather than just publishing this valuable list every month in the FALCON Method Newsletter, we make additional efforts to explore another segment of the stock market that sometimes yields hidden gems. While quality and growth are the key factors for EVA Monsters, it is the valuation that drives returns for these once-beloved dividend darlings now found in the bargain bin. This is why we call this category “Fallen Angels.”

Upon completing Step #7, we have the list of the most attractive stocks for investment, and our process has reached its ultimate goal.

The Falcon Method Newsletter is your trusty companion, bringing you top 10 stock picks every month straight to your inbox. Say goodbye to endless hours of market analysis and hello to reliable passive income, long-term growth, and peace of mind.

The FALCON Method Newsletter offers access to institutional-level data and professional analyses for the best price possible.

With a 7-day free trial, you’ve got nothing to lose but stress! Dive into a community of smart investors and let your money work for you, not the other way around. Start your journey towards simplified, effective investing today!

In the previous part of The Compounder’s Path Series, we learned why a thoughtful screening process can serve as a compass to guide you through the labyrinth of the financial markets. We also noted that employing the right metrics can give you an advantage in the game, even though being a successful investor requires much more than mere number-crunching.

Let’s pick up where we left off and demonstrate why relying solely on a quantitative process is flawed, even when using a highly sophisticated screening framework that addresses accounting distortions. By the end of today’s article, you will understand why you must depend on comprehensive qualitative analysis and cannot avoid the rigorous task of getting to know your investment targets.

Couldn’t Keep a Lid on Success: Lessons from a Tonic Manufacturer’s Struggles

Let’s delve into the example of Fever-Tree, the once-shining early player in the premium tonic market. The company was among the pioneers in this space, with a compelling slogan: “If three-quarters of your drink is the mixer, mix with the best.” It makes a lot of sense; how often have you opted for cheap tonic water to mix with your gin, saving only a small amount compared to Fever-Tree or another premium brand?

Initially, the numbers were impressive. In the four years following its 2014 IPO, Fever-Tree’s sales and Economic Value Added (EVA) generation soared. The firm boasted sky-high return on capital and EVA margin figures, propelling it to the forefront of quantitative quality-growth screeners. Notably, this led to an explosive increase in its share price, which surged more than 20-fold, creating significant wealth for early shareholders. Take a look:

However, this is where the harsh reality set in. Competitors began flooding the market, and Fever-Tree’s brand turned out not to be a differentiating factor justifying a high price for its tonics. Inflationary pressures were the icing on the cake in a negative sense. Even though one could argue that these are transitory in effect, especially as the U.S. has become Fever-Tree’s biggest market and it continues to operate almost entirely from the UK, we contend that Fever-Tree’s declining quantitative performance revealed deeper issues beneath the surface.

As Fever-Tree’s EVA generation began to approach zero, just as one would expect in a fiercely competitive market with diminishing pricing power, it became evident that the company was seriously lacking in the competitive advantage department. To borrow a famous adage from Warren Buffett, “A rising tide floats all boats… only when the tide goes out do you discover who’s been swimming naked.” Take a look at what happened to the company’s EVA generation and how its market value plummeted as a result:

Here comes the million-dollar question: Could a thorough deep-dive analysis have predicted the demise of Fever-Tree’s competitive edge? In our view, starting with the right questions would have certainly helped steer us in the right direction.

• Does the firm have an enduring moat that protects its outstanding profitability from new market entrants?
• Does it possess a strong brand, along with a marketing budget that can bolster its brand power and translate into a widening moat over time?
• Does it maintain a distribution network and global bottling operation that would raise barriers to entry in the market?
• Are established beverage giants planning to enter the market with competing products, potentially outnumbering up-and-coming pure-play players like Fever-Tree due to their deep pockets and global distribution power?

We asked all these questions when Fever-Tree first appeared on our quantitative radar and anonymously concluded that the company’s moat was far from durable. Consequently, we decided against its inclusion in our EVA Monster universe.

The moral of the story is that exceptional quantitative metrics can be a symptom of a wide moat, but only the presence of durable forces that keep competitors at bay can lead to sustained above-average returns. Therefore, the cause-and-effect relationship should not be misunderstood. Just because you find a stock that ranks very high in your otherwise well-developed filtering system, it does not mean it will be a great investment. Far from it, you should never skip the qualitative deep-dive process before making an investment decision.

To help tilt the odds in your favor, you should aim to maintain a shortlisted “investable universe” of great companies that you closely follow. This way, you can form an educated opinion and make a contrarian bet when you have an unshakeable understanding of the underlying business, differentiating between temporary trouble and existential threats. This aligns with the saying that success occurs when opportunity meets preparation.

To quote Buffett again, “The best thing that happens to us is when a great company gets into temporary trouble… We want to buy them when they’re on the operating table.”

In summary, you need to have a clear understanding of the investment case. Too little information can be detrimental, while too much information, without distilling the key factors, can lead to unwanted information overload.

Here’s the most common pitfall: underestimating the effort required to form a qualitative opinion.

You might believe that understanding a company can happen overnight. Unfortunately, that’s not the case. In our experience, our team of three analysts spends several days conducting intensive research on a candidate before we form an opinion and construct our financial models based on well-informed inputs.

We believe that a minimal analysis entails reviewing the past few years’ annual reports, listening to management answering questions on various analyst calls, and assessing the competitive landscape and underlying secular trends to gain a comprehensive understanding of the business’s quality and growth characteristics. Our viewpoint and conviction about a company are then shaped through months of monitoring company-related news, listening to podcasts, reading research papers, and engaging in an ongoing analysis within the team to arrive at conclusions that define our target entry prices.

This can be a formidable task for individual investors, but we are here to assist you. In the last part of The Compounder’s Path Series, we will demonstrate how you can simplify your investment process and achieve the results you desire by dedicating a few hours to this topic each month. Stay tuned.

In the first part of The Compounder’s Path Series, we delved into the crucial foundation of a sound investment strategy: building an Investable Universe grounded in historically proven factors.

We discovered that a manageable number of companies, carefully selected, can make the difference between financial success and a risky gamble. We also touched upon why blindly following your instincts or other people’s advice can be a one-way ticket to disappointment.

Today, let’s dive deeper into the heart of a successful screening process, i.e. metrics.

These numerical indicators are the compass guiding you through the labyrinth of the financial markets. They help you make informed decisions, reduce risks, and maximize returns, assuming that you follow the right approach. And while being a successful investor takes way more than pure number-crunching, understanding and employing the right metrics can put you ahead in the game.

Let’s see what inexperienced investors get wrong most of the time.

The Metric Maze

One common misconception is the belief that more metrics will guarantee better investment outcomes. It’s easy to fall into this trap, thinking that an arsenal of 37 different metrics will provide a clearer picture of a company’s potential. However, the reality is quite the opposite.

While a multifaceted approach is undoubtedly warranted, meaning you should consider various business characteristics like business quality, profitability, or growth, the key is to keep things as simple as possible while ensuring that your screening process is “good enough”.

When you drown yourself in a sea of numbers, it’s not clarity that emerges but rather confusion and complexity. You will not know how to prioritize among the myriad of metrics available to you. This overload can be paralyzing and lead you down a path of uncertainty.

In our experience, 4-5 metrics can tell you all you need to know about a business number-wise. When it comes to building a great screening process, the quality of inputs used in your analysis is far more important than quantity.

The Valuation Trap

Another pitfall that ensnares many aspiring investors is the tendency to prioritize valuation as the initial step in their screening process. While valuation is undoubtedly an essential factor to consider, placing it at the forefront of your analysis can lead to several issues that undermine your investment journey.

Imagine, for a moment, that your primary focus is to identify stocks trading at a discount to their intrinsic value. It seems like a reasonable approach, doesn’t it?

However, this methodology often leads to a revolving door of new names every time you run your screening process. This results in an overwhelming amount of work, tracking, and analysis, which we discussed in our previous article can be an exhausting and inefficient pursuit.

Furthermore, by primarily focusing on valuation, you may inadvertently cast a wide net that encompasses a vast variety of businesses. Some of these may be high-quality firms, while others (or shall we say the overwhelming majority) will be less reputable companies that lack a sustainable competitive advantage, or even bordering on the ‘junk’ category. These companies might appear statistically cheap at first glance, but delving deeper, you will find that they carry excessive risk and lack the fundamental characteristics of solid investments.

Consider this scenario: You’ve identified a stock trading at an unbelievably low price compared to its earnings or book value. It’s tempting to think you’ve found a hidden gem. However, what’s beneath the surface?

Does the company have any sort of “moat” around its business which protects it from competitors? Does it have sufficient growth prospects and a great management team? Focusing foremost on valuation can lead you astray in these situations, that’s why we firmly believe that valuation metrics should not be a part of your initial screening process.

The Deception of Conventional Accounting Metrics

Here comes (arguably) the most important mousetrap to consider: the undue trust placed in conventional accounting metrics as the sole determinant of a company’s true economic value creation. You have to accept the fact that accounting is not meant to help investors but to calculate taxes. Therefore, accounting numbers are easily manipulated, and any multiple based on these reports is misleading and dangerous.

We have written an entire article about proving these points, but just to summarize things:

1. Accounting treats shareholders’ equity as free money (distorts earnings)
2. Accounting treats two identical investment decisions differently (distorts earnings)
3. Accounting provides ample room for management to play with certain items (distorts cash flow)
4. P/E, P/FCF, P/EBITDA, P/BV, ROI, and ROIC are also badly distorted, thus not suitable to base serious investment decisions on them
5. Even the PRICE component in the commonly used multiples leads to distortions because of differences in capital structures (distorts all multiples using the P component)
6. Earnings growth can be high and still lead to shareholder value destruction (not all growth is good)

To illustrate our point, let’s examine the case of AT&T between 2009 and 2022.

During these 13 years, AT&T’s EPS (the shaded green area) grew from $1.60 per share to $2.57, representing a growth of over 55% over this timeframe. However, here is the puzzling discrepancy – the share price remained largely stagnant over this time.

How can this be? The answer lies in the deceptive nature of how EPS (or FCF, EBITDA, and so on) can paint a completely false picture of true business performance.

Enter Economic Value Added (EVA), a metric that delves beyond the superficial and provides a more accurate reflection of a company’s economic profit generation. EVA takes not only the earnings into account but also the cost of capital, offering a holistic view of how effectively a company generates wealth for its shareholders.

In simple terms, EVA is a metric that measures the firm’s profit remaining after:

1. Deducting all costs adjusted for accounting distortions one by one.
2. Including the cost of giving the firm’s investors a full, fair, and competitive return on their investment in the business.

EVA is a comprehensive net profit score that charges for all capital used, including shareholders’ equity, which is falsely considered free money under GAAP accounting.

Let’s check how AT&T fared in the EVA framework between 2009 and 2022.

The trajectory of the red bar shows a whole different story. Despite the apparent EPS growth, the company’s EVA has remained relatively flat, suggesting that while accountants were happy with the results, the firm did not increase economic value for its owners.

Stagnating levels of EVA have led to a flat share price, no matter how much EPS has grown.

Let’s look at the polar opposite of what we have just witnessed: consider the case of Amazon between 2007 and 2015.

During this period, Amazon’s EPS showed little to no growth (it was $0.06 per share both in 2007 and 2015). To the casual observer, this might seem perplexing, as the company’s share price skyrocketed, growing sevenfold during the same period.

How is it possible for a company to experience stagnant EPS and yet see its market value increase substantially?

The answer lies in the stellar performance of Amazon’s EVA per share, which grew nearly in line with its share price, expanding sixfold during those eight years.

In short, you must put the quality of the data you are using above everything else when putting together a robust screening process. (And that is the reason why we spend tens of thousands of dollars annually on getting this institutional-level data at the FALCON Method.)

Crafting a Superior Screener: Focus on Quality and Growth

So far, we’ve uncovered the pitfalls associated with relying solely on conventional accounting metrics and explored case studies that demonstrate the power of true economic profit generation through EVA.

Now, let’s delve into how we would construct a top-tier stock screener that will most likely guide you toward promising investments.

Our solution lies in focusing on 2-2 key metrics that revolve around quality and growth. For instance, we use Return on Capital (ROC), EVA Margin, Sales Growth (on a 5-10-year horizon), and EVA Growth for our screening process, since these metrics, when used in tandem, offer a comprehensive view of a company’s quality and true value creation.
(You could substitute EVA with Net Income or Free Cash Flow, albeit you have seen how wildly these metrics can converge from economic reality).

As a next step, we would use these 4 metrics to narrow down the field of stocks, by assigning a composite Quality-Growth score (giving an equal weight to each factor) to every company in our screener. After ranking these from top to bottom, we would select the 50-100 firms that fared most favorably in this selection process.

You may ask, why should we narrow our focus to high-quality, durable-growth companies? Let us present two compelling reasons.

Reason 1: Double-Digit Fundamental Return Potential

First and foremost, these quality compounders possess the unique ability to ensure a high, double-digit fundamental return potential. This means that their growth, combined with dividends and the effect of buybacks, can provide market-beating performance on their own.

In other words, you don’t necessarily need the tailwind of favorable valuation to achieve superior returns. This also eliminates the need for constantly finding new investment targets, mitigating the so-called “reinvestment risk”.

These companies are the only viable option for a true buy-and-hold strategy, where you can sit back and watch the wonderful effects of decades-long compounding. You don’t need to come up with new ideas every month, every year.

To help you better understand this concept, here is a snapshot of how the quantitative metrics and fundamental return of our Investable Universe compared with the S&P 500 over the past 10 years. You can see that we strived to establish a pool of companies where we get market-beating quality and growth characteristics, leading to an exceptional fundamental return historically.

Reason 2: Good Businesses Seldom Become Bad Businesses (and vice versa)

Great companies seldom turn bad overnight, and conversely, businesses that have consistently demonstrated poor quality don’t miraculously transform into industry leaders.

The chart below shows a GMO study that proves that companies with high ROC levels tend to remain market leaders, and firms that could not produce outsized returns on their invested capital cannot improve on this metric over time. There is no “mean reversion”. That’s why it’s important to stay invested in good companies and avoid subpar businesses like a plague.

This principle forms the backbone of our quality-focused screening process, and it’s a crucial factor in creating an Investable Universe that maintains relative stability over time.

Today, we have shown you how we would go about building a quantitative system that generates a few tangible stocks that are worth your attention out of more than 10,000. The quantitative boxes these companies have ticked are essential, but they represent only the tip of the iceberg.

To grasp the full narrative, we must also explore the qualitative aspects. In the third part of The Compounder’s Path Series, we will shed light on why you need to dig deep into those businesses that ranked high in your screening process, to earn a spot and more importantly, to remain in your Investable Universe. Stay tuned for more!

Welcome to The Compounder’s Path, an exclusive 4-part series where we will demystify the art of making money in the stock market, offering you a step-by-step roadmap to harness the power of time, consistency, and a proper investment strategy. Whether you’re a novice or an experienced investor, we are certain that these key principles will significantly upgrade your financial library and take you to the next level.

We will cover:

• Why building your Investable Universe is crucial for success, and what is the best approach
• Why conventional accounting metrics are hugely misleading, supported by several case studies
• What metric is best suited to measure true shareholder value creation
• The importance of qualitative analysis alongside a quantitative screening process
• And how you can master all this in just a few hours every month

Embarking on a journey into the world of stock investing can often feel like stepping into a dense forest of endless possibilities. The vast array of companies and industries can be overwhelming, and even the most experienced investors could feel lost sometimes. Our goal is to guide you through this intricate maze, helping you to develop a system that you can count on through your journey to financial freedom.

Let’s get straight into it.

The Broader, the Better? Not Quite!

The very first step in your investing journey should be the establishment of a selection process, to arrive at a pool of companies that you are most interested in. This is what we call the birth of our “Investable Universe”, which contains the list of firms we want to gain a deeper understanding of. While the concept of building your Investable Universe sounds simple, there are many culprits along the way. Let’s check on what we believe investors get wrong most of the time.

Your initial instinct might be to cast a wide net, thinking that the broader the selection, the better your chances of finding the best opportunities. After all, if I search as broadly as possible, I should have the best chance of finding mispriced stocks that Mr. Market (temporarily) threw into the garbage bin.

In theory, this strategy sounds like a winner, and you’re not alone in believing it. However, you may have heard the saying that goes, “Jack of all trades, master of none.” In the world of stock investing, casting too wide a net can often leave you overwhelmed and confused, with no clear path to success.

Did you know that there are tens of thousands of public companies available globally? Narrowing the pool to one country, one sector, or one “theme” will still leave you with thousands of stocks.

That’s an enormous pool of potential investments, and even without going into details as to how much time you have to spend on familiarizing yourself with just one company, it is easy to acknowledge that your Universe should contain a maximum of 50-100 firms. In our experience, anything beyond that, you are surely left with either 1) an insurmountable amount of research, or 2) a very shallow understanding of every company inside the Universe.

Now that you understand why developing an Investable Universe is central to your investing success, let’s examine the most common pitfalls we see investors fall into repeatedly.

Pitfall #1: Relying on Gut Feeling

Imagine this: a friend enthusiastically tells you about a “hot” stock or a promising industry, and you think you’ve struck gold. With unwavering faith in your instincts, you dive headfirst into the investment, convinced that you’ve discovered the “diamond in the rough.” It sounds thrilling, but the reality is often different. Much different.

Take a look at this process-outcome matrix which always serves as a guiding post for us when we make investment decisions.

The truth is that while luck can certainly play a role in successful investments, relying solely on your gut feeling places you squarely in the “dumb luck” quadrant. Even a bad process will yield a good outcome sometimes, while it is also true that a good process will not always result in a runaway success. Understanding this concept has had a major impact on us.
Unfortunately, luck is not a reliable strategy for consistent success in the complex world of stock investing.

What you truly need is a well-defined process – a system backed by historically proven factors that can consistently deliver you the results you desire. You want to find yourself in the upper-left section of the matrix, where a good process leads (given that you provide enough time for a strategy to bear fruit) to your “deserved success”. Having a reproducible system is the only way that allows you to invest your hard-earned money with confidence, month after month.

Pitfall #2: Falling for the Illusion of Solo Superstars

It’s hard not to be starstruck by high-profile investors who seem to consistently hit home runs while venturing into the most obscure corners of markets. You might think of legendary investors like Mohnish Pabrai, known for his captivating Turkish adventures where admittedly, he managed to 3-5x his investments in just a few years. His successes are inspiring, and we often hear stories of similar, renowned investors’ extraordinary journeys.

But here’s the inside scoop: even he admits openly that he receives dozens of tips and ideas from his extensive network of value investors. This network is something that the average investor doesn’t have access to, making it (unfortunately) an uneven playing field. Not to mention that comparing yourself to the greatest minds in the field who have honed their craft through decades of experience may not serve your interest.

All in all, we firmly believe that trying to replicate the processes and portfolios of world-class asset managers is not a reliable path for the everyday investor (even if the financial media and some investment services would like you to believe this.)

On top of that, one aspect we haven’t touched on yet is the concept of survivorship bias. Have you ever wondered how many failures these investors have encountered before discovering their successes? For every multi-bagger, there are likely numerous investments that didn’t pan out as expected. But you don’t read about those, do you?

Consider the immense amount of time they’ve spent on researching ideas that ultimately provided no value. These failures are rarely publicized, and this skewed perspective can lead aspiring investors down a misleading path. While it’s essential to learn from successful investors, it’s equally crucial to recognize that behind every victory are countless attempts that didn’t hit the mark.

Pitfall #3: The Perils of a Selection Process That Produces an Ever-Changing Investable Universe

The reality is that researching new stock prospects thoroughly is a time-consuming endeavor. Imagine you’ve found a stock screener that perfectly aligns with your investment goals and spits out companies that become a part of your Investable Universe. You diligently run it every month, just after your paycheck hits your bank account.

But here’s the catch: every month, your screener spits out dozens of new candidates that meet your criteria. It’s like trying to sip from a firehose of information.

In our experience, evaluating these candidates comprehensively is no small feat. It can take several days or even weeks just to get to know the story behind each of these companies well enough to feel comfortable investing in them. You’ll find yourself buried in annual reports, presentations, earnings call transcripts, and more.

This level of in-depth analysis is a luxury that full-time investors can afford, but for those balancing investing with other responsibilities, it’s a challenging task. An alternative would be to update your Investable Universe every year, but if the 50-100 candidates are completely different than the year before, you are left with a daunting task once again.

The key takeaway here is that even a good selection process yields little value to you if its results are changing too frequently. The stability of the outcomes (in terms of companies worthy of your analysis) is an equally important aspect to consider.
When you’re inundated with too many analytical tasks and you’re unsure about some of the firms you’re considering, you’re not getting any closer to achieving true financial freedom in every sense of the word.

Let’s recap what we have covered so far as a successful recipe for stock selection:

You should establish your Investable Universe. With the help of this, you reduce the pool of candidates to a manageable number, ideally not more than 50-100 companies. More is not better. You need a list that doesn’t overwhelm you with countless options but instead offers a reasonable selection to work with effectively.

Rely on historically proven factors. Don’t confuse your gut feeling and the stock tips of friends with a true selection system. Your investments should be based on factors with a track record of success. Only this can ensure that you have a good process that is consistently reproducible, and will prove to be very valuable over the long term. Don’t confuse “dumb luck” (which every fool can enjoy once in a while) with “deserved success”.

Avoid drawing false conclusions from the successes of renowned investors. They have resources that are not available to the average investor, while the survivorship bias ensures that you only hear about their home-run investment, and not much about their countless failures.

Don’t underestimate the value of consistency. Your Investable Universe should remain relatively stable over time. Constantly changing stocks can disrupt your focus, and lead to an overwhelming amount of due diligence needed.

But there’s one more essential element to consider. Your Investable Universe is only as good as the indicators and metrics you use in your filtering process. When you’re sifting through the stock market to separate the wheat from the chaff, it’s crucial to have the right lenses on.

You might believe that financial metrics like operating margins, earnings per share (EPS) or free cash flow (FCF) growth, and price-to-earnings (P/E) multiples can form the foundation of a successful investment process. However, the reality is that these traditional accounting metrics can paint a completely false picture regarding true shareholder value creation, and are far from sufficient.

In the second part of The Compounder’s Path Series, we will prove why these traditional ratios do not provide the comprehensive insight you need. We’ll show you why it’s vital to employ the best and most fitting metrics available that show a true picture of a company’s economic profit generation, to make informed investment decisions and not squander your precious time.

Investing should be an empowering and enriching journey, and with the right tools and knowledge, you can take huge leaps towards achieving financial freedom. Stay tuned for more!

We never wanted the FALCON Method to be a black box. Hence, we are eager to invite you behind the scenes and give an inside view of how we operate our stock selection process. Lately, Italian company Moncler (known for its pricey jackets) provided an insightful example of how a purely quantitative approach could lead investors astray and why one should never omit the labor-intensive qualitative deep-dive phase.

As per our structured process, we begin by filtering the vast universe of global stocks, applying various EVA-based quality and growth criteria. Those that stand out in every regard and thus seem capable of producing double-digit fundamental returns (as a combination of value-creating growth and shareholder returns) make up our shortlist of EVA Monsters worthy of in-depth analysis and close monitoring. The last time our team did the annual screening process, Moncler comfortably qualified as an EVA Monster candidate based on its double-digit sales growth, EVA Margin, and other quantitative characteristics. Although this business is nowhere near the size of the heavyweight luxury companies, we still found that learning more about this supertrends-supported industry may be useful regardless of how Moncler fares in our qualitative framework. And this is where things got interesting.

The deeper we dove, the more warning signs emerged. Firstly, Don Thompson’s book, The Curious Economics of Luxury Fashion, classifies Moncler as a premium brand. The key insight is that premium labels typically sell for 40-60% of the price level of luxury brands (such as Louis Vuitton or Hermès), so Moncler must compensate for this shortcoming to produce those spectacular numbers that landed it on our EVA Monster shortlist. And compensate they do! How about a “Made in Romania” badge for starters?

While real luxury powerhouses invest heavily to maintain control of the supply chain, from the crocodile farm to store décor and stick with certain countries for the final assembly or manufacturing (as seen on product labels), others are closing production sites in their home countries, considering such cost optimization a logical progression. These decisions must always be analyzed and evaluated within the context of a strategy, as luxury’s ability to sustain high prices and profitability is governed by strict rules. Cost-conscious relocators are, in reality, discontinuing their luxury strategy in favor of a fashion strategy, without explicitly admitting this. In fact, the luxury strategy is a specific business model; fashion is another, governed by a completely different set of working principles. (Burberry and Prada are great examples of this shift, while Moncler was never a true luxury brand in the strictest sense.)

Moncler’s tangled heritage began in France in 1952. (You may notice it is still a toddler compared to seasoned luxury counterparts.) Then, a 2003 acquisition uprooted the 50-year brand and moved it to Italy, marking the beginning of its premiumization, direct-to-consumer push, and global expansion. While the numbers leave nothing to be desired, Moncler follows a finely-tuned fashion strategy rather than the classic luxury playbook. No artisanship, no “handmade in France” label, but cheap Romanian production along with dubious luxury positioning. And this is far from the last red flag we discovered.

The product portfolio also qualifies as thought-provoking. Outerwear contributes 70-80% of the company’s revenue, as Moncler is essentially a mono-category, mono-brand, and mono-product business. Being the category leader in down outerwear may not be enough for long-term success as the barriers to entry are relatively low in this sub-segment, and the exposure to short fashion cycles is also a negative. (Comparatively, the leather goods and hard luxury segments boast decade-long product cycles. Think about the Hermès Birkin bag or the Rolex Daytona watch.) Overall, we consider the apparel category the least attractive and most vulnerable within the luxury space, so Moncler’s positioning is not to our liking. Our research also revealed that Moncler items lack both resale and investment value, in stark contrast with traditional luxury products like Louis Vuitton bags, Rolex watches, and Ferraris (or even Nike’s collectible shoes). A second-hand Moncler jacket exhibits no luxury traits, which is quite telling.

The mono-brand business model can work for actual luxury powerhouses like Hermès and Chanel. Those companies have the haute couture and leather bags at the top of their product pyramids, while the widely available $30 Chanel lipstick at the bottom doesn’t diminish the brand’s perceived value. We wouldn’t bet on Moncler replicating such a structure, as it badly misses the top components and is essentially an apparel firm. To make matters worse, this is a fashion company that happens to sell its products at a luxury price.

Truth be told, Moncler’s down outerwear category has grown at over 20% annually since 2009, recently driven by the wardrobe casualization trend, and they benefited greatly through excellent strategic execution. From 2012 to 2022, Moncler more than doubled its global store count, and the company aims to expand selling space by mid- to high-single-digits in the next few years. This is a remarkable growth story, hence the quantitative EVA Monster qualification. Yet the puffer coat and jacket revolution may attract competition from new players and established brands expanding into the category, and Moncler doesn’t seem to possess any kind of moat that would warrant its luxury pricing in a more competitive environment. This brings us to the key question: How long do you think this company can keep up its value-creating growth without a protective moat?

Remo Ruffini has been the CEO since 2003, and it’s no exaggeration that all the success is attributable to his leadership. That being said, we don’t feel too comfortable betting on this CEO to recreate his magic over and over with different brands to keep his firm’s growth characteristics intact. Looking under the hood revealed that Moncler is lightyears from the true luxury businesses we are keen to invest in for decade-long periods.

Exceptional management can be the icing on the cake once we identify a company with a durable moat, but we’d generally stay away from mediocre businesses (except for our Fallen Angel picks, where we aim for mean reversion over a ~3-year period). In the luxury space, Hermès, Ferrari, Richemont, LVMH, and Kering qualify as reasonable investment candidates, while Moncler is out of our EVA Monster universe after the in-depth analysis revealed some alarming shortcomings.

Want to learn more about our stock ranking methodology and evidence-based investment approach? Start with this blog post!

Or read more like this in the Beyond Dividends book.

With this series, we’d like to give you some perspective on the companies in our distinguished EVA Monster universe. This rare breed of quality-growth stocks is worthy of your attention, and getting to know these businesses may pay off handsomely down the road.

As a quick recap, EVA Monsters have three things in common:

• They earn high returns on the capital they employ.
• They have growth opportunities that allow them to reinvest most of their cash flows at high rates of return.
• They have a sustainable competitive advantage (that Warren Buffett calls “moat”), which prevents their competitors from taking away their extraordinary profitability.

These characteristics tend to result in a strong (double-digit) fundamental return potential, meaning that no valuation tailwind is necessary to get great investment results with EVA Monsters. (These case studies explain this pretty well.)

As Charlie Munger said:

“Over the long term, it’s hard for a stock to earn a much better return that the business which underlies it earns. If the business earns 6 percent on capital over 40 years and you hold it for that 40 years, you’re not going to make much different than a 6 percent return – even if you originally buy it at a huge discount. Conversely, if a business earns 18 percent on capital over 20 or 30 years, even if you pay an expensive looking price, you’ll end up with one hell of a result.”

We also shared the math proof of why buying EVA Monster stocks at a fairish valuation makes perfect sense for long-term investors. (Look for the “math example” in this post to alleviate your doubts.)

To round off the short introduction, we (1) try to avoid overpaying for EVA Monsters, (2) closely monitor the fundamental performance and management’s capital allocation decisions throughout our holding period, and (3) hold our positions as long as the underlying investment thesis remains intact, ideally for decades, to let compounding do the heavy lifting.

Without further ado, numbers prove that Monster Beverage (MNST), the best-in-class energy drink brand possesses true EVA Monster characteristics and is thus worthy of your close attention. As long as you agree with us that caffeinated beverages are not ripe for an inevitable downturn due to changes in consumer preferences, Monster could be a great addition to any quality-growth-focused portfolio.